A smartphone-based system to quantify dexterity in Parkinson's disease patients.
Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder (Shin et al., 2016) and is characterized by degeneration of dopaminergic neurons in the substantia nigra. A common treatment for PD is levodopa. Over the course of the disease, levodopa dose and timing of intake have to be adjusted to optimize the therapeutic effect (Schapira, 2009) . PD is a multidimensional, progressive disease and patients have different symptom profiles, which makes it difficult for healthcare professionals and patients themselves to assess and manage PD symptoms. From the clinical point of view, it is challenging to remotely and frequently determine the current motor state M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT of the patient to determine whether the patient is under-medicated (a state in which the PD motor symptoms such as bradykinesia, tremor, rigidity, and others appear) or over-medicated (the appearance of hyper-kinetic movements related to excessive levels of medication). Therefore, assessing the current motor state of the patient is essential for deriving an optimal treatment strategy.
The current state of the art for assessing PD symptoms in clinical routine and studies is by using clinical rating scales based on observations and judgments of clinicians and medical history. The most commonly used clinical rating scale is the Unified PD Rating Scale (UPDRS) (Martínez-Martín et al., 1994) , which is used to evaluate the presence, severity and progression of PD symptoms as well as symptom fluctuations. However, clinician-based measurements are not able to capture variations in symptoms on a day-to-day basis since they only reflect one brief point in time. To reveal the full extent of patients' condition and prevent a recall and reporting bias, the motor symptoms need to be captured frequently, before and after medication (Isacson et al., 2008) . Combining the elements of common rating scales with frequent self-assessments and objective tests can also help with covering more aspects of the disease than what can actually be obtained by clinical ratings alone.
Recent advances in information and communication technologies have enabled remote and continuous monitoring of motor symptoms (Maetzler et al., 2013) . Previous studies have shown that such technologies provide accurate and valid objective assessment of symptoms. It was previously reported that they may assist in identifying motor functions (On , Off and dyskinesia) (Andong Zhan et al., 2016; Galli et al., 2014) . The technology-based measures not only generate more valid endpoints for clinical studies but also can be useful in routine clinical care. There is a growing interest in investigating how useful the measures are when providing feedback to patients to increase their symptom and treatment outcome awareness (Bot et al., 2016) .
From the technological point of view, data from different kinds of sensors during standardized tests and passive monitoring of physical activity have been previously analyzed and processed using signal processing and machine learning methods (Griffiths et al., 2012; Zeng et al., 2016) . There are different studies with the focus on quantifying various motor symptoms. Some have focused on assessing motor dysfunctions in upper extremities (Heldman et al., 2014; , some on gross motor symptoms like gait (Mariani et al., 2010) , while others on combination of both. For instance, Tsipouras et al. (2012) analyzed data from accelerometers and gyroscopes, which were placed on different parts of patients' bodies with the aim of quantifying drug-induced involuntary movements or dyskinesia, using Fourier transform. A similar approach was employed by Salarian et al. (2007) to quantify bradykinesia and tremor. Other studies have focused on analyzing data from upper limbs during standardized tasks like finger tapping (Heldman et al., 2014; Shima et al., 2009) , digital spiral analysis (Saunders-Pullman et al., 2008) and quantitative digitography (Taylor Tavares et al., 2005; Giovannoni et al., 1999) .
As an alternative to wearable sensors-based systems, some research groups have focused on assessing dexterity performance of PD patients by analyzing upper limb motor data collected by means of touch screen devices (Saunders-Pullman et al., 2008; Liu et al., 2005; Haubenberger et al., 2011) . The touch screens of the smartphones record physical properties of movements that can be produced either by a pen tip or finger with great spatial and temporal precision. Such smartphone measurements were previously used for assessing different fine motor dysfunctions like tremor (Haubenberger et al., 2011) , dyskinesia (Liu et al., 2005) , drawing impairments and global tapping performance (Memedi et al., 2013) . Quantitative measures during alternating tapping tests and digital spiral analysis have been previously used as measures of bradykinesia (Giovannoni et al., 1999) and severity of PD symptoms (Saunders-Pullman et al., 2008) . To our knowledge, there is no study reporting an approach where tapping and spiral drawing test data were combined in data-driven manner and related to objective measures such as various clinical ratings and actual treatment.
The purpose of this paper was to investigate whether a smartphone-based system, which consists of tapping and spiral drawing tests, can be used for quantifying dexterity in advanced PD. The paper reports clinimetric properties of smartphone-based measures of dexterity including correlations to M A N U S C R I P T
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clinical rating scales, test-retest reliability, sensitivity to treatment interventions, and ability to differentiate between tests performed by patients and healthy controls.
Materials and Methods 2.1 Participants
Nineteen advanced PD patients and 22 healthy controls were recruited in a single center, open label, single dose clinical trial in Uppsala, Sweden (Table 1, Senek et al., 2017) . Written informed consent was given after approval by the regional ethical review board (in Uppsala, Sweden). 
Gender

Data collection
The trial included a single levodopa-carbidopa dose experiment for the PD patients, where both patients and healthy controls were asked to perform dexterity tests (tapping and spiral drawing) using a smartphone before and at specific time intervals after a dose was given (Senek et al., 2017; . For the patients, the dose administered was 150% of their individual levodopa equivalent morning dose to follow transitions between Off, On, and On with dyskinesia motor states. Up to 15 samples per PD patient were collected, one measurement at baseline (20 minutes prior to dosing), one at the time of dose administration (0 minutes) and thereafter follow-up measurements at 20, 40, 80, 110, 140, 170, 200, 230, 260, 290, 320 , and 360 minutes after dose administration. The healthy controls were asked to perform the tests, 8 times each, at time point 0 (first test) and then at 20, 40, 60, 80, 110, 140, and 170 minutes, without receiving any medication.
On each test occasion, subjects performed upper limb motor tests (tapping and spiral drawings), using a smartphone ( Figure 1 ). The smartphone had a 4" (86 x 53 mm) touch screen with a 480 x 800 pixels and recorded both position (x and y coordinates) and time-stamps (in milliseconds) of the pen tip. The subjects were instructed to be seated on a chair and perform the tests using an ergonomic pen stylus with the device that was placed on a table and supporting neither hand nor arm. During tapping tests, they were asked to alternately tap two fields, as shown on the screen of the device, as fast and accurate as possible, using first right hand and then left hand. The time to complete a tapping test was 20 seconds. During the spiral tests, the subjects were instructed to trace a predrawn Archimedes spiral as fast (within 10 seconds) and accurately as possible, from the center out, using the dominant hand. The test was repeated three times per test occasion. The total number of measurements with the smartphone for PD patients was 285, and for healthy controls was 176.
Clinical assessments of motor symptoms
Along with smartphone-based measurements, patients were video recorded while performing standardized motor tasks according to UPDRS at the above-mentioned time points. The recorded videos were presented in a randomized order to three movement disorder specialists, so that the ratings were blinded with respect to time from dose administration. The specialists rated three UPDRS-part III (motor examination) items including UPDRS item #23 (finger tapping), UPDRS #25 (rapid alternating movements of hands), and UPDRS #31 (bradykinesia), according to the definitions of the motor examination part of the UPDRS (Fahn et al., 1987) . For items #23 and #25 the specialists were asked to assign a single score per time point without reference to any hand. The specialists also rated dyskinesia on a severity scale from 0 to 4 (Goetz et al., 2008) and overall mobility according to Treatment Response Scale (TRS) (Nyholm et al., 2005) , ranging from -3 (very M A N U S C R I P T
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Off) to 0 (On) to +3 (very dyskinetic). For every scale, mean scores per time point for the three specialists were calculated and used in subsequent analysis. 
Data processing and Analysis
2.4.1
Feature extraction The raw dexterity data were processed with time series analysis methods to calculate 37 spatiotemporal features, which represent the severity of symptoms. Different kinematic quantities, including time, distance, speed, and velocity were used as primary signals to be processed and analyzed using time-and wavelet-domain methods. First, 20 tapping and 10 spiral features were calculated based on previous publications. The first 30 features are listed in Table 2 .
Tapping features (Reference to previous works)
(1) Total Number of taps (Macleod et al., 2010) (2) Mean tapping time difference between two fields (Yahalom et al., 2004) (3) Mean tapping speed from right to left (Memedi et al., 2013) (4) Mean tapping speed from left to right (Memedi et al., 2013) (5) Coefficient of variation of tapping speed from right to left, (6) Coefficient of variation of tapping speed from left to right (Taylor Tavares et al., 2005) (7) Mean distance from the centers of the fields (Arora et al., 2015) (8) Coefficient of variation of distances from the center fields (Arora et al., 2015) (9) Overall distribution of the taps (Memedi et al., 2013) (10) Mean distance from center (Arora et al., 2015) (11) Mean tapping speed per cycle (Memedi et al., 2013) (12) The absolute mean difference between the first and second part of the time series signal (Memedi et al., 2013 ) (13) Approximate entropy (ApEn) measure of the two parts of the time series signal (Memedi et al., 2013) (14) Measure of tapping speed reduction (Arora et al., 2015) (15) Measure of tapping reaction time (Yahalom et al., 2004) (16) Overall trend of tapping reaction time during the test trial (Yahalom et al., 2004) (17) ApEn measure of mean tapping speed (Memedi et al., 2013) (18) The amount of irregularity in vertical tap distance (Memedi et al., 2013) (19) Measure of variation in distance between the two fields (Arora et al., 2015; Memedi et al., 2013) M A N U S C R I P T
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(20) Measure of irregularity caused by time variations during tapping Spiral features (Reference to previous works) (21) Mean drawing speed (Stanley et al., 2010) (22) Coefficient of variation of speed (23) Skewness of the speed (24) Radial velocity (Hess et al., 2014) (25) Mean time difference (Banaszkiewicz et al., 2009) (26) Global minima of the drawing speed, (27) Global maxima of the drawing speed (28) ApEn measure of drawing speed, (29) ApEn measure of radial velocity (Memedi et al., 2016) (30) Coefficient of variation of high frequency wavelet coefficients by discrete wavelet transform (DWT) In addition to the aforementioned features, 7 new spiral features were calculated and used in the feature set. The rationale behind including more features was to cover more symptom information from the dexterity tests.
(31) Kurtosis (fourth standardised moment) of the drawing speed signal was calculated as following:
where ‫ݏ‬ is the distribution of the drawing speed per second, µ is the mean of s, σ is the standard deviation of s, and E ‫ݏ(‬ − ߤ) is the expected value of the ‫ݏ‬ − ߤ quantity. Kurtosis computes a sample version of this population value and measures how outlier-prone the distribution of the speed is. Computing the kurtosis of drawing speed was to quantify the amount of delays, abruption and continuation of movements. Interpolating Polynomial (PCHIP) approximation and numerical integration over the segments of the spiral drawing (Hoogendam et al., 2014; Miralles et al., 2006) . The spiral drawing curve length is associated with the deviations from the template (original spiral) and was used as a measure to quantify the impaired drawing. (35) The area of the spiral drawing was calculated using the trapezoidal method to extract the region of the curve drawn by the subjects. This is done by breaking the whole area down into trapezoids with easily computable areas. The integration over an interval of every two consecutive points from spiral drawing was calculated and accumulated together to obtain the total area. Equation (2) shows the formula to calculate the integration between the two points.
Where N is the total number of points, and the spacing between each point is equal to the scalar value ି ଶ
. There is a relation between the size of the spiral and the speed of the drawing movements. According to (Longstaff et al., 2003) , it is more likely that the larger spirals will be drawn faster than the smaller spirals. The increasing size of the spiral drawing increases the M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT coordination requirements, it is therefore concluded that larger spirals are drawn with greater degree of variability than smaller spirals. (36) Spiral drawing total time is defined as the time that was required to draw the spiral on the smartphone. It is the time difference between first and last captured points from the smartphone. (37) The x and y points of the spiral drawing were retrieved from the smartphone with their respective time stamps. An ideal Archimedean spiral has a constant speed during the execution, which means the time-stamp at each point increases constantly. Slower the movements greater the time difference between points. The time differences between consecutive points were mapped over time. Using the alternating nature of the derivatives, the magnitudes of the identified peak points were calculated from a series of time differences. In addition, the sum of the magnitudes was calculated to represent the amount of delays in the spiral drawing execution. Since there were two trials that were performed during tapping tests (first right hand and then left hand), individual features of both trials were averaged and used in the following analysis. Similarly, for spiral tests the average of the features were calculated for the three trials.
Principal component analysis
To reduce the dimensions of the features but keep the most important and related information into a smaller set, principal component analysis (PCA) using the correlation matrix method was applied on the 37 features. Theoretically, PCA is a linear dimension reduction technique that uses a rectangular transformation to convert the set of correlated features into a set of values of linearly uncorrelated variables. Seven principal component scores (PCs) having eigenvalues higher than 1 were retained and used in subsequent analysis. Applying this threshold resulted in retaining 71% of the variation in data.
Machine learning
The PCs were used as predictors to supervised machine learning methods used to map to the mean ratings of the three movement disorder specialists on the clinical rating scales used in the clinical trial. Four machine learning methods were evaluated, using the Weka datamining toolkit (Eibe Frank, et al., 2016) : support vector machines (SVM), linear regression (LR), regression trees (RT), and multilayer perceptron artificial neural networks (MLP). A stratified 10-fold cross validation was applied to test the performance of the machine learning methods. For each of the five scales, separate models were built and tested.
Statistical analysis
The performance of the machine learning methods was assessed by correlation coefficients between the predicted and mean clinical ratings. One-way consistency intra-class correlation coefficients (ICC) were calculated to assess the agreements between the three specialists' ratings and test-retest reliability of mean specialist and smartphone-based scores between the first two baseline measurements. To test the relevance of the tapping and spiral features when used as predictors in the machine learning methods bidirectional stepwise regression approach was employed using sumUPDRS (the sum of UPDRS #23, UPDRS #25 and UPDRS #31) ratings of the three individual raters as response variables. To investigate differences in mean PCs between the groups patients and healthy controls, linear mixed effects models based on a restricted maximum likelihood estimation method were employed. Group was considered as a fixed effect and subject ID as a random effect. The relative ability to detect change from baseline (no medication) to follow up time points when patients were on medication was assessed by effect sizes. To calculate effect sizes, ANOVA models were fitted for each time point after the baseline test; first test and second test; first test and third test, and so on. A high effect size indicates that a scale is sensitive to treatment response (Goetz et al., 2013) . The statistical analyses were performed in R and Minitab statistical software.
Results
Feature evaluation
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The 17 features that were the most relevant as predictors of sumUPDRS when using individual ratings of the three movement disorder specialists as response variables are listed in Table 3 . Six (3 tapping and 3 spiral) of the 17 features were selected as significant predictors of sumUPDRS by the three separate regression models. The remaining features were either selected by two or one regression model. 
Inter-rater agreements
ICCs between the three specialists were moderate to strong: 0.61 for UPDRS #23, 0.52 for UPDRS #25, 0.58 for UPDRS #31, 0.65 for sum of the UPDRS #23, UPDRS #25 and UPDRS #31 (sumUPDRS), 0.8 for TRS, and 0.67 for dyskinesia. These results indicate that for all scales there is an inter-rater variability to some degree. A mean rating per time point and item was calculated and used as a dependent variable when training and evaluating the machine learning methods.
Correlations between Predicted and Clinical Scores
The correlation coefficients between mean clinical ratings and predicted scores ranged from weak to moderate ( 
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Test-Retest Reliability
The ICCs between the first two baseline measurements were calculated. The data for this analysis included measurements at test occasions before patients received the dose and at the moment the dose was administered. The results showed that the mean clinician ratings had better test-retest reliability than the scores derived by the SVM model ( Table 5 . ICCs between the first two baseline measurements for smartphone-based scores and mean ratings of the three clinicians.
Sensitivity to treatment changes
The most sensitive scales were the clinician-based TRS and dyskinesia. The PC1 had lower sensitivity but, in general, was capable of capturing changes in symptom severity in response to levodopa medication. It could also capture improvements/deteriorations in symptoms throughout the levodopa test cycle i.e. during transitions between different motor states of patients, from Off to On (normal mobility) and/or On with dyskinesia and the wearing Off effects (Figure 2) . Figure 2 . Sensitivity assessment of PC1 and mean ratings of the three movement disorder specialists on the three UPDRS items, TRS and dyskinesia across the levodopa test cycle for all patients. The first data point in the X axis represents the change in scores between the first two baseline (without medication) measurements. The second data point represents the change in scores between first baseline and third measurement, and so on. Number of tests per time slot: 0 (n=19), 20 (19), 40 (n=19), 60 (n=19), 80 (n=18), 110 (n=17), 140 (n=17), 170 (n=17), 200 (n=17), 230 (n=17), 260 (n=14), 290 (n=14), 320 (n=11), and 360 (n=11) . 
Separation between patients and healthy subjects
When assessing the ability of the PCs to differentiate between tests performed by patients and healthy controls, the mean scores of 3 (PC1, PC2 and PC4) out of the 7 PCs were significantly different between the two groups (p<0.005). Summary statistics of the 7 PCs for both the groups are shown in Table 6 . PC1 PC2 PC3 PC4 PC5 PC6 PC7 P-value <0.001 <0.001 0.9 <0.001 0.1 0.9 0.1
Healthy controls
Mean SD 
Discussion and conclusions
In this study, smartphone-generated dexterity measurements were used to quantify the motor performance of PD patients during repeated tapping and spiral drawings tasks. The methods developed in this study were evaluated using measurements from 19 PD patients during a single levodopa dose experiment and 22 healthy controls. The obtained results indicate that the methods could capture motor symptoms reasonably well as compared to the mean assessments of three movement disorder specialists on three items of UPDRS-III, TRS and dyskinesia scales. The correlations were weak to moderate between the scores derived by the methods and the mean clinical ratings, indicating that tapping and spiral drawing tests capture relevant symptom information corresponding to the clinical rating scales. In contrast to the clinical rating scales, another advantage with the current system is that PD-related outcomes can be captured and assessed more frequently.
During clinical assessments, the movement disorder specialists observed the patients while performing standardized motor tasks as defined in the UPDRS scale where the highest weight was given to the symptoms that were prominent during gross motor performance e. g., walking ability. During tapping and spiral drawing tasks, only fine motor movements could be recorded by the smartphone touch screen. This may explain the moderate agreements between SVM and mean clinician ratings, which in turn suggests further work for complementing and fusing dexterity measurements with data from wearable sensors or inertial measurement units of smartphones that are collected during gross motor tasks. Furthermore, based on the correlation coefficients (Table 4) we can notice that the tapping and spiral drawing tests contained relevant information about motor function of patients. In addition, the results from the feature selection (Table 3) indicate that not all of the tapping and spiral features were equally represented in the regression models when using individual ratings on sumUPDRS as response variable. These results may reflect the moderate agreements on the clinical ratings by the three raters.
The clinimetric properties of the motor tests were previously assessed in a longitudinal 36 months clinical trial in Sweden and a two weeks trial in Italy (Memedi et al., 2013; . In those studies, it was found that data from such tests can be used to measure PD progression over time and to separate patients in different disease stages. Spiral drawing tests were also shown to be useful in automating the process of scoring the Off symptoms and dyskinesia in PD patients (Sadikov et al., 2017) . The effect of handedness in the right-handed patients (84% of the patients) was investigated and the results indicated that the effect of handedness was more prominent than the effect of the side in which PD symptoms started since they had better tapping results with the right hand than with the left hand. Smartphones have previously been tested in detecting and assessing the severity of PD symptoms. (Arora et al., 2015) combined smartphone data after the PD patients M A N U S C R I P T
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performed a battery of tests including voice, posture, gait, finger tapping, and reaction time. The results indicated that multimodal smartphone data can be useful for diagnosis purposes as well as monitoring progression of PD symptoms.
In our study, dexterity measurements of the smartphone were related to corresponding clinical ratings and changes in symptoms during single dose experiments. The results show that combining spatiotemporal features extracted from tapping and spiral drawing data can be used to detect treatment-related changes in advanced PD. Although the PC1 had a lower sensitivity when compared to mean clinical ratings on TRS and dyskinesia, we can conclude that PC1 alone could significantly detect changes in symptoms to the first test on medication (20 minutes post-dose, Figure 2 ). In addition, the PC1 could follow transitions between motor states across the levodopa test cycle since it had similar trends as the TRS and dyskinesia scale. These results suggest that tapping and spiral drawing tests with the smartphone can detect movements reasonably well related to under-and over-medication. This could be due to the fact that raw tapping and spiral data were processed with ApEn and DWT methods. The ApEn in general measures the amount of irregularity in a signal and could be useful in capturing different irregular movement patterns during the test trial, which could be related to dyskinesia. The DWT employs a multiresolution analysis of a signal by separating lowfrequency components from high-frequency components. In our work, the level and variation in frequency components was derived by calculating mean and standard deviation of the wavelet coefficients. These features could be useful in quantifying movements related to under-and overmedication.
As a limitation of this study, there was a considerable amount of inter-rater variability. This is a natural problem when dealing with subjective ratings. For instance, in the study performed by (Heldman et al., 2014) the raters differently weighted speed, amplitude and rhythm while observing video recordings of PD patients during finger tapping tasks. The discrepancies in assessments could be related due to the fact that in our study there was no training of the raters and/or due to the natural within-and between-rater variability when using scales (Post et al., 2005) . One possible step to reduce the inter-rater variability from the mean rating would be to include more raters. Future research will focus on improving the performance of the methods by including spatiotemporal features from wearable sensors (e.g. during gait) into a feature set that can be used during datadriven modelling. In addition, it would be interesting to investigate correlations between standard dexterity tests like Purdue Pegboard test and the measures derived from the tapping and spiral drawing tests of the smartphone.
In conclusion, the results presented in this paper indicate that tapping and spiral drawing tests of the smartphone contain relevant symptom information for detecting and assessing PD dexterity. The results suggest that the tests can be useful in detecting changes in motor symptoms related to treatment. 
